Head-to-head · WeighScore
Freya Meds vs Ilant Health
The verdict
Freya Meds takes it — 58.6/100 to 56.8/100, but only just.
Freya Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Freya Meds is a GLP-1 specialist offering compounded semaglutide ($250–$297/mo) and compounded tirzepatide ($332–$390/mo). Ilant Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Freya Meds | Ilant Health |
|---|---|---|
| WeighScore | 58.6/100 | 56.8/100 |
| Grade | C | C |
| Scorecard rank | #364 | #408 |
| Semaglutide | $297/mo (compounded) | Not disclosed |
| Tirzepatide | $390/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #364 · C
Strengths
- GLP-1 specialist — not a multi-category telehealth
- Price includes unlimited doctor consultations, monthly group calls, and a dietitian consultation
- Both semaglutide and tirzepatide available
- Multi-month discount on quarterly billing
- Claims 450,000+ enrolled
Where it loses points
- No visible LegitScript or PCAB accreditation
- Above-average pricing ($250–$390/mo)
- Compounded only — no brand-name options
- Now serves 49 U.S. states (one state excluded; specific exclusion not named)
Graded #408 · C
Strengths
- Value-based, outcomes-driven obesity care model
- Includes GLP-1 medications with transparent drug pricing for sponsors
- Care team of board-certified obesity providers and behavioral specialists
- Dietitians and peer navigators support adherence
- Data-driven stratification targets the right interventions
Where it loses points
- Distributed via employers and health plans, not direct cash-pay
- Individuals generally cannot enroll without sponsor coverage
- No public consumer pricing for GLP-1
- Access gated behind organizational buyers
- Not suited to consumers wanting direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.